title: Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1).
abstract: BACKGROUND
  In ulcerative colitis the intestinal somatostatin content is reduced. Somatostatin has several immune-inhibitory effects. In vitro it diminishes activity of intestinal lymphocytes and peripheral blood monocytes. Its long-acting analogue octreotide has beneficial effects on mucosal damage in acute experimental acetic acid colitis in rats.
  
  
  OBJECTIVE
  To determine the potential benefits of octreotide as a treatment for patients with severe ulcerative colitis treated with high dose corticosteroids.
  
  
  METHODS
  Forty-two patients with severe ulcerative colitis (more than 10 points on the Powell-Tuck scoring system and mucosal disease Heatly grade III or IV).
  
  
  METHODS
  In a multi-centre, double blind, placebo-controlled trial all patients were treated with oral 5-ASA (1.6-2.4 g daily) and high dose corticosteroids (tapering off from 60 to 80 mg daily). They were randomly assigned to receive subcutaneous placebo (n = 22) or octreotide 500 microg (n = 20) thrice daily during 21 days. Clinical and endoscopic disease activity, histology and laboratory parameters were obtained during the study period.
  
  
  RESULTS
  Clinical disease activity for both octreotide and placebo were not significantly different at baseline and after 21 days of treatment. Endoscopic disease activities (mean +/- SD) changed from 12.5 +/- 4.7 to 7.2 +/- 5.3 for octreotide, and from 11.5 +/- 5.0 to 5.0 +/- 3.4 for placebo (NS). Seven patients from both groups received additional treatment (colectomy (n = 6), cyclosporin (n = 1)). Adverse events occurred equally in both groups.
  
  
  CONCLUSIONS
  Subcutaneous administration of octreotide 500 microg thrice daily is not of additional benefit as adjuvant therapy to high dose corticosteroids in severe ulcerative colitis.
authors.affiliation: Dept of Gastroenterology and Internal Medicine, University Hospital Rotterdam, The Netherlands.
authors.forename: Jeroen D
authors.initials: JD
authors.lastname: van Bergeijk
authors.forename: J H Paul
authors.initials: JH
authors.lastname: Wilson
authors.forename: Ole Haage
authors.initials: OH
authors.lastname: Nielsen
authors.forename: Christian
authors.initials: C
authors.lastname: von Tirpitz
authors.forename: Anna-Lusa
authors.initials: AL
authors.lastname: Karvonen
authors.forename: I
authors.initials: I
authors.lastname: Lygren
authors.forename: Andreas
authors.initials: A
authors.lastname: Rädler
authors.forename: Helge L
authors.initials: HL
authors.lastname: Waldum
authors.forename: Chris J J
authors.initials: CJ
authors.lastname: Mulder
authors.forename: S
authors.initials: S
authors.lastname: Friis
authors.forename: Solomon
authors.initials: S
authors.lastname: Tefera
authors.forename: Johannes F W
authors.initials: JF
authors.lastname: Hoogkamer
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005765:Gastrointestinal Agents; D005938:Glucocorticoids; D019804:Mesalamine; D011239:Prednisolone; D015282:Octreotide; D011241:Prednisone